Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 4—April 2005


Ross River Virus Disease Reemergence, Fiji, 2003–2004

Philipp Klapsing*†, J. Dick MacLean*Comments to Author , Sarah Glaze‡, Karen L. McClean‡, Michael A. Drebot§, Robert S. Lanciotti¶, and Grant L. Campbell¶
Author affiliations: *Montreal General Hospital, Montreal, Quebec, Canada; †McGill University Health Centre, Montreal, Quebec, Canada; ‡Royal University Hospital, Saskatoon, Saskatchewan, Canada; §Health Canada, Winnipeg, Manitoba, Canada; and; ¶Centers for Disease Control and Prevention, Fort Collins, Colorado, USA

Main Article


Results of tests of patients’ serum for antibodies to selected alphaviruses*

IgM results†
PRNT titers‡
Patient Interval (d)§ RRV BFV RRV BFV SINV
1 10 Positive Negative 320 <10 <10
21 Positive Negative 1,280 <10 <10
141 Equivocal Negative 160 ND ND
2 16 Positive Negative 5,120 <10 ND
33 Positive Negative 5,120 <10 ND

*Ig, immunoglobulin; PRNT, plaque-reduction neutralization test; RRV, Ross River virus; BFV, Barmah Forest virus; SINV, Sindbis virus; ND, not done.
†IgM-capture enzyme immunoassay; samples tested at 1:400 dilution; positive samples had a positive-to-negative (P/N) absorbance ratio >3.0; equivocal samples had a P/N ratio 2.0–3.0 (10); no test for anti-SINV IgM was available.
‡90% plaque-reduction endpoints; >10 is considered positive (11).
§From onset of illness to serum collection.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO